Abstract:Background: LDA triggers biosynthesis of endogenous anti-inflammatory molecules, aspirin-triggered 15-epi-lipoxin A4 (15-epi-LXA4), which may counteract inflammatory process of preeclampsia (PE), and play role in LDA's mechanism of action in PE prevention in high-risk patients. Objective: Investigate the effects of daily LDA on levels of 15-epi-LXA4 in pregnancies at high-risk for developing PE. Materials and methods: Secondary analysis of multi-centered randomized controlled trial investigating effects of daily LDA (60 mg) in high-risk pregnancies. Maternal samples were drawn at three points: before LDA initiation (13-26 weeks' gestation), 24-28 weeks' gestation (at least two weeks after LDA) and 34-36 weeks' gestation. 15-epi-LXA4 levels were measured by ELISA. Results: Analysis included 82 patients: 63 receiving daily LDA and 29 receiving daily placebo starting between 13 and 25 weeks gestation. Prior to randomization, baseline 15-epi-LXA4 levels were similar between both groups (75.9 pg/mL [IQR; 63.8-114.0] vs 136.2 pg/mL [52.4-476.2]; p = 0.10). Patients receiving daily LDA were noted to have significantly increased levels of 15-epi-LXA4 after LDA administration (136.2 pg/mL [IQR; 52.4-476.2] vs 1758.2 pg/mL [905.4-6638.5]; p < 0.001). They also had higher 15-epi-LXA4 levels compared to those receiving placebo at 24-28 weeks' (50.3 [38.1-94.2] vs 1758.2 [905.4-6638.5]; p < 0.001 and 34-38 weeks' gestation (57.9 [41.9-76.7] vs 2310.3 pg/mL [656.9-10609.4]; p < 0.001). After LDA administration in the second trimester, patients who developed PE had decrease in 15-epi-LXA4 levels compared to those without PE (942 pg/mL [348.3-1810.3] vs 1758.2 pg/mL [905.4-6638.5]; p = 0.129). Conclusion: Daily LDA administration increases 15-epi-LXA4 levels in high-risk pregnancies for PE. In LDA group, pregnancies complicated by PE have lower levels of 15-epi-LXA4 compared to pregnancies without PE.

Treatment of Lipoxin A4 and Its Analogue on Low-Dose Endotoxin Induced Preeclampsia in Rat and Possible Mechanisms

Preeclampsia is Associated with A Deficiency of Lipoxin A4, an Endogenous Anti-Inflammatory Mediator

Lipoxin A4 suppresses angiotensin II type 1 receptor autoantibody in preeclampsia via modulating caspase-1

Effect of lipoxin A4 on lipopolysaccharide-induced endothelial hyperpermeability.

Lmwh Inhibits Tnf-Alpha And Il-6 In Placental Villous Explants And Its Effects Are Attenuated By Tlr-4/Nf-Kappa B P65 Blocking In Jeg-3 Cells

Single Administration of Ultra-Low-dose Lipopolysaccharide in Rat Early Pregnancy Induces TLR4 Activation in the Placenta Contributing to Preeclampsia.

Effect of Lipoxin A<sub>4</sub>on Lipopolysaccharide-Induced Endothelial Hyperpermeability

Lipoxin A4: The double-edge sword in mice pregnancy.

Glucocorticoid Exposure Induces Preeclampsia via DampeningLipoxin A4, an Endogenous Anti-Inflammatory and Proresolving Mediator

The Intervention Effect of Aspirin on a Lipopolysaccharide-Induced Preeclampsia-Like Mouse Model by Inhibiting the Nuclear Factor-Κb Pathway†

Low-Dose Aspirin Prevents Kidney Damage in LPS-Induced Preeclampsia by Inhibiting the WNT5A and NF-κB Signaling Pathways

Low-Dose Aspirin Prevents Kidney Damage in LPS-Induced Preeclampsia by Inhibiting the WNT5A and NF-B Signaling Pathways

Ulinastatin ameliorates preeclampsia induced by N(gamma)-nitro-l-arginine methyl ester in a rat model via inhibition of the systemic and placental inflammatory response

Luteolin prevents TNF-α-induced NF-κB activation and ROS production in cultured human placental explants and endothelial cells

Low-dose aspirin increases 15-epi-lipoxins A4 in pregnancies at high-risk for developing preeclampsia

Pravastatin Alleviates Lipopolysaccharide-Induced Placental TLR4 Over-Activation and Promotes Uterine Arteriole Remodeling Without Impairing Rat Fetal Development

Ameliorative effects of aspirin against lipopolysaccharide-induced preeclampsia-like symptoms in rat by inhibiting the pro-inflammatory pathway.

Evaluation of the Effects of Uncaria Rhynchophylla Alkaloid Extract on LPS-induced Preeclampsia Symptoms and Inflammation in a Pregnant Rat Model.

LPS-Induced Hypotension in Pregnancy: The Effect of Progesterone Supplementation

The preventive effect of low-dose aspirin in a PPAR-γ antagonist treated mouse model of preeclampsia

Therapeutic Effect of Alpha Lipoic Acid in a Rat Preclinical Model of Preeclampsia: Focus on Maternal Signs, Fetal Growth and Placental Function